Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 61.55M | 56.83M | 74.78M | 92.97M | 101.98M |
Gross Profit | 21.44M | 19.45M | 22.05M | 38.08M | 48.58M |
EBITDA | -16.91M | -24.10M | -16.71M | 10.59M | 21.52M |
Net Income | -31.79M | -24.02M | -41.00M | 875.00K | -6.01M |
Balance Sheet | |||||
Total Assets | 103.29M | 59.44M | 92.10M | 118.89M | 130.40M |
Cash, Cash Equivalents and Short-Term Investments | 5.17M | 3.69M | 6.58M | 25.91M | 27.33M |
Total Debt | 100.76M | 67.43M | 58.26M | 99.16M | 104.34M |
Total Liabilities | 138.47M | 83.38M | 94.28M | 119.21M | 132.62M |
Stockholders Equity | -35.18M | -23.95M | -2.18M | -319.00K | -2.22M |
Cash Flow | |||||
Free Cash Flow | -14.26M | -14.26M | -6.90M | 4.55M | 13.56M |
Operating Cash Flow | -4.19M | -11.56M | -921.00K | 13.24M | 23.75M |
Investing Cash Flow | -22.97M | 24.76M | -5.98M | -8.69M | -10.20M |
Financing Cash Flow | 28.81M | -16.04M | -12.32M | -6.02M | -2.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $28.21M | -14.40 | -35.47% | ― | 27.05% | 55.03% | |
48 Neutral | $19.32M | ― | 77.20% | ― | -4.02% | -6.31% | |
44 Neutral | $7.10M | ― | -358.07% | ― | ― | ― | |
41 Neutral | $16.19M | -0.04 | -163.82% | ― | -25.02% | 85.08% | |
38 Underperform | $10.17M | -0.54 | -352.75% | ― | -1.90% | 87.72% | |
38 Underperform | $7.08M | -0.25 | 547.20% | ― | 4.99% | 22.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Trinity Biotech has released its Annual Report for 2024, which includes key documents such as the Company Secretary’s letter, Notice of Annual General Meeting, and AGM Proxy Card. The report, dated September 8, 2025, provides insights into the company’s financial performance, strategic direction, and management structure, highlighting the leadership of CEO John Gillard. This announcement is significant for stakeholders as it outlines the company’s operational and financial status, potentially impacting its market position and investor confidence.
On September 2, 2025, Trinity Biotech announced it regained compliance with Nasdaq’s listing requirements, specifically the $1.00 minimum bid price and the minimum market value of publicly held shares. This follows a period of non-compliance noted on March 14, 2025, and subsequent improvements in share price and market value by August 2025. The resolution of these compliance issues is significant for Trinity Biotech’s continued listing on the Nasdaq, which is crucial for maintaining investor confidence and market presence.
On August 20, 2025, Trinity Biotech announced it received regulatory approval to commence offshore and outsourced manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic move is expected to enhance the company’s financial performance by expanding gross margins, freeing up working capital, and reducing fixed costs, thereby supporting broader profitability and growth objectives. The transition to a more cost-effective and scalable production model marks a critical milestone in Trinity Biotech’s transformation strategy, positioning the company for long-term financial health and improved industry positioning.
On August 14, 2025, Trinity Biotech announced that it received regulatory approval from the New York State Department of Health to begin offering its FDA-cleared PreClara™ preeclampsia testing service. This approval is a significant milestone in the company’s maternal health strategy, enhancing its position in the U.S. diagnostics market. The PreClara™ test provides crucial insights for managing hypertensive disorders in pregnancy, potentially reducing neonatal costs by over $10 million per 1,000 patients. This development also supports the future introduction of Trinity Biotech’s PrePsia™ technology for early pregnancy risk assessment.
On August 12, 2025, Trinity Biotech announced breakthrough clinical trial results for its redesigned continuous glucose monitoring (CGM) sensor, marking a significant milestone in diabetes management technology. The trial confirmed that the new needle-free glucose sensor provides accurate readings over a 15-day period without finger-stick calibration, enhancing user convenience and reducing costs. This advancement positions Trinity Biotech to expand access to CGM technology in a growing market, projected to reach $28 billion by 2030, by offering a more affordable and sustainable product.
On August 7, 2025, Trinity Biotech announced the launch of its FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test, a significant advancement in maternal health diagnostics. This new testing service, developed in collaboration with Thermo Fisher Scientific, will be available through Trinity Biotech’s New York-based reference laboratory in Q3 2025. The test is designed to provide clinicians with critical insights for managing hypertensive disorders of pregnancy, potentially leading to significant cost savings and improved patient outcomes. This strategic milestone enhances Trinity Biotech’s position in the maternal health sector and reflects its commitment to addressing urgent healthcare needs.
On July 24, 2025, Trinity Biotech announced the unveiling of CGM+, an AI-native platform designed for the $260 billion AI wearables market. This innovative device integrates glucose, cardiovascular, temperature, and activity monitoring into a single wearable, aiming to provide comprehensive health insights through real-time AI analysis. The CGM+ platform is expected to position Trinity Biotech at the forefront of AI-driven healthcare, offering new commercial opportunities and expanding its market presence beyond traditional diagnostics.
On July 1, 2025, Trinity Biotech announced it had reached a profitability inflection point, a major milestone in its strategic turnaround. The company reported its financial results for the quarter ended March 31, 2025, and projected a positive Adjusted EBITDA from Q3 2025 onwards. This achievement follows significant operational restructuring, including offshoring manufacturing, which has reduced costs and positioned the company for sustainable profitability. Trinity Biotech is now focusing on expanding its product offerings, including diabetes care and HIV tests, and advancing its pipeline of diagnostic tests, such as preeclampsia and prostate cancer tests. The company also continues to develop its next-generation continuous glucose monitoring solution, aiming to capture a significant share of the growing global market.